Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional recurrence in patients with non-small cell lung cancer.
PURPOSE
To retrospectively evaluate the effectiveness and safety of CT-guided (125)I seed brachytherapy (CTISB) in 38 non-small cell lung cancer (NSCLC) patients with locoregional recurrence (LRR).


METHODS AND MATERIALS
In total, we analyzed 38 NSCLC patients with LRR treated with percutaneous CTISB in our hospital between 2001 and 2008; among them, 15 also received combined chemotherapy: 1-6 cycles (median, 2) of platinum-based regimens. The change in tumor volume was evaluated based on followup contrast material-enhanced CT or positron emission tomography scans.


RESULTS
The median Day 0 dosimetry was as follows: The volume treated with the prescription dose (V100) was 96.3% (90.1-123.5%), and the minimum dose received by at least 90% of the tumor volume (D90) was 124.8 Gy (116.0-130.7 Gy). The median duration of the followup period calculated from the first CTISB treatment was 22.5 months (range, 8-98 months). Two months after CTISB, complete response, partial response, and progressive disease were observed in 50%, 37%, and 8% of patients, respectively. Median overall survival (OS) after CTISB was 21 months (95% confidence interval, 7.4-34.6), and the rates of 2-year OS, progression-free survival, and local control were 47.4%, 39.5%, and 83.5%, respectively. Both univariate and multivariate analysis indicated that D90 was significant prognostic factors for OS and progression-free survival.


CONCLUSION
For selected NSCLC patients with limited LRR, CTISB is effective and can provide a high rate of local cancer control with minimal trauma.
['Huo|Xiaodong|X|', 'Wang|Huixing|H|', 'Yang|Jingkui|J|', 'Li|Xiaodong|X|', 'Yan|Weiliang|W|', 'Huo|Bin|B|', 'Zheng|Guangjun|G|', 'Chai|Shude|S|', 'Wang|Junjie|J|', 'Guan|Zhiyu|Z|', 'Yu|Zhengtao|Z|']
D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D001918:Brachytherapy D002289:Carcinoma, Non-Small-Cell Lung D059248:Chemoradiotherapy D018572:Disease-Free Survival D005260:Female D006801:Humans D007457:Iodine Radioisotopes D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D009364:Neoplasm Recurrence, Local D011184:Postoperative Period D011879:Radiotherapy Dosage D061089:Radiotherapy, Image-Guided D012189:Retrospective Studies D015996:Survival Rate D014057:Tomography, X-Ray Computed
Brachytherapy Locoregional recurrence Iodine-125 seed Non–small cell lung cancer Surgery